Altre lingue MannKind Corporation

Azioni

MNKD

US56400P7069

Tempo reale stimato Cboe BZX Altri mercati azionari 19:19:55 09/07/2024			Variaz. 5gg	Var. 1 gen.
5,365 ^USD	-0,46%		+6,95%	+47,79%

22/06	MannKind Corporation annuncia i risultati positivi a 17 settimane dello studio INHALE-3	CI
29/05	MannKind concorda un accordo di licenza incrociata con Pulmatrix	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions	22/06
MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study	22/06
MannKind Corporation - Inhale-3 Study Results to be presented during a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions	06/06
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions	05/06
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	30/05
MannKind Agrees to Cross License Deal With Pulmatrix	29/05
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix	29/05
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	29/05
MannKind : First Quarter 2024 Earnings Call Presentation	09/05
MannKind: Q1 Earnings Snapshot	09/05
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	08/05
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M	08/05
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update	08/05
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment	06/05
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	06/05
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	06/05
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024	01/05
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30/04
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	30/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MannKind Corporation

Azioni

MNKD

US56400P7069

Altre lingue

Filtri